403 related articles for article (PubMed ID: 29905462)
1. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
[TBL] [Abstract][Full Text] [Related]
2. Effect of Glucose on Liposome-Plasma Protein Interactions: Relevance for the Physiological Response of Clinically Approved Liposomal Formulations.
Palchetti S; Digiacomo L; Pozzi D; Zenezini Chiozzi R; Capriotti AL; Laganà A; Coppola R; Caputo D; Sharifzadeh M; Mahmoudi M; Caracciolo G
Adv Biosyst; 2019 Feb; 3(2):e1800221. PubMed ID: 32627369
[TBL] [Abstract][Full Text] [Related]
3. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona.
Caracciolo G
Nanoscale; 2018 Mar; 10(9):4167-4172. PubMed ID: 29450412
[TBL] [Abstract][Full Text] [Related]
4. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
5. Characterization of doxorubicin liposomal formulations for size-based distribution of drug and excipients using asymmetric-flow field-flow fractionation (AF4) and liquid chromatography-mass spectrometry (LC-MS).
Ansar SM; Mudalige T
Int J Pharm; 2020 Jan; 574():118906. PubMed ID: 31805309
[TBL] [Abstract][Full Text] [Related]
6. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
7. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
8. Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.
Papi M; Caputo D; Palmieri V; Coppola R; Palchetti S; Bugli F; Martini C; Digiacomo L; Pozzi D; Caracciolo G
Nanoscale; 2017 Jul; 9(29):10327-10334. PubMed ID: 28702661
[TBL] [Abstract][Full Text] [Related]
9. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes.
Peretz Damari S; Shamrakov D; Varenik M; Koren E; Nativ-Roth E; Barenholz Y; Regev O
Int J Pharm; 2018 Aug; 547(1-2):648-655. PubMed ID: 29913218
[TBL] [Abstract][Full Text] [Related]
10. Determination of non-liposomal and liposomal doxorubicin in plasma by LC-MS/MS coupled with an effective solid phase extraction: In comparison with ultrafiltration technique and application to a pharmacokinetic study.
Xie Y; Shao N; Jin Y; Zhang L; Jiang H; Xiong N; Su F; Xu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():149-160. PubMed ID: 29175695
[TBL] [Abstract][Full Text] [Related]
11. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
12. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence lifetime microscopy unveils the supramolecular organization of liposomal Doxorubicin.
Tentori P; Signore G; Camposeo A; Carretta A; Ferri G; Pingue P; Luin S; Pozzi D; Gratton E; Beltram F; Caracciolo G; Cardarelli F
Nanoscale; 2022 Jun; 14(25):8901-8905. PubMed ID: 35719059
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome-wide elucidation of liposomal formulations for anticancer drug delivery.
Li Y; Wang M; Huang BW; Ping Y; You J; Gao JQ
Int J Nanomedicine; 2017; 12():8557-8572. PubMed ID: 29238192
[TBL] [Abstract][Full Text] [Related]
15. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC-LIF: liposomal carrier for enhanced drug delivery.
Ho JA; Fan NC; Jou AF; Wu LC; Sun TP
Talanta; 2012 Sep; 99():683-8. PubMed ID: 22967611
[TBL] [Abstract][Full Text] [Related]
17. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
18. Low Intensity Ultrasound Mediated Liposomal Doxorubicin Delivery Using Polymer Microbubbles.
Yu FT; Chen X; Wang J; Qin B; Villanueva FS
Mol Pharm; 2016 Jan; 13(1):55-64. PubMed ID: 26567985
[TBL] [Abstract][Full Text] [Related]
19. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
20. Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer.
Palchetti S; Caputo D; Digiacomo L; Capriotti AL; Coppola R; Pozzi D; Caracciolo G
Pharmaceutics; 2019 Jan; 11(1):. PubMed ID: 30650541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
